Corpus ID: 80553425

Varicella Zoster Infection Associated withPharmacological JAK-STAT Inhibition viaRuxolitinib in Myeloproliferative Diseases

  title={Varicella Zoster Infection Associated withPharmacological JAK-STAT Inhibition viaRuxolitinib in Myeloproliferative Diseases},
  author={S. H. Aktimur and G. K. Akkoyunlu and U. Malkan and N. Demirel and M. Turğut and I. Haznedaroglu},
  journal={The Journal of medical research},
Ruxolitinib phosphate is an inhibitor drug of the JAK family of protein kinases. The results from two Phase III studies in myelofibrosis (COMFORT-I, COMFORT-II) demonstrate the effectiveness of Ruxolitinib in patients with primary myelofibrosis (MF), post-polycythemia vera myelofibrosis (PV-MF) and post-essential thrombocythemia myelofibrosis (ET-MF). On the other hand, Ruxolitinib affects several cytokines (IL1, IL6 and TNF-a) and other immune processes (dendritic cells function and T-cell… Expand
1 Citations
A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management.
What is known about the disease pathogenesis is outlined, an approach to reaching the diagnosis is discussed, the prognosis of myelofibrosis is reviewed, and current therapeutic strategies are detailed. Expand


Rates of Infection in Myelofibrosis Patients Treated with Ruxolitinib
Ruxolitinib had to be discontinued due to the severity of the infection in 2 pts, while the others either had a dose reduction or no dose alteration, and has been linked to increased incidence of opportunistic and non-opportunistic infections. Expand
Practical management of patients with myelofibrosis receiving ruxolitinib
The aims of this article are to provide a brief overview of ruxolitinib therapy, to discuss some common adverse events associated with rUXolit inib therapy and to provide clinical management recommendations to maximize patients’ benefit from ruxolinib. Expand
Ruxolitinib for the treatment of myelofibrosis.
Low toxicity, alleviation of constitutional symptoms, weight gain and improvement in general physical condition were observed with ruxolitinib treatment which may substantially improve quality of life in patients with myelofibrosis. Expand
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.
Data indicate that clinical efficacy and survival improvement may occur across different molecular subsets of patients with MF treated with ruxolitinib. Expand
Changes in Quality of Life and Disease-Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results
The effect of RUX on PV-related symptoms and QoL measures in the RESPONSE trial was evaluated and it was found that the severity of pruritus and its interference on daily life improved with RUX. Expand
The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo.
It is demonstrated that ruxolitinib significantly affects DC differentiation and function leading to impaired T-cell activation and the findings may also explain the outstanding anti-inflammatory and immunomodulating activity of JAK inhibitors currently used in the treatment of MF and autoimmune diseases. Expand
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
Comparison of discontinuation rates and reasons for stopping the therapy to those reported for other 51 patients in the phase 1/2 trial, and 155 ruxolitinib-treated patients in phase 3 COMFORT-I study, suggest that continued therapy with ruxolinib at optimal doses contributes to the benefits seen, including OS benefit. Expand
Visceral Varicella-Zoster after bone marrow transplantation: report of a case series and review of the literature
Visceral involvement with varicella-zoster virus infection can occur as a late complication after both allogeneic and autologous BMT, and clinicians should be aware of this potentially treatable and often lethal complication. Expand
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis
Reductions in spleen volume and TSS and evidence of improved survival relative to placebo across subgroups were consistent with those seen in the COMFORT‐I population, confirming that ruxolitinib is an effective therapy for the spectrum of MF patients studied in COMFort‐I. Expand
Ruxolitinib for myelofibrosis
In conclusion, based on the trials included in the present study, the use of ruxolitinib is beneficial in the treatment of MF. Expand